Bexsero market report points to wider vaccine use through 2035

The Business Research Company released a 2026 report on the global Bexsero market, projecting growth through 2035 as vaccination programs expand and public health funding rises. The report highlights North America’s current lead and says Asia-Pacific is positioned for the fastest growth.

Why it matters: - Bexsero is a meningococcal group B vaccine used to prevent invasive meningococcal disease, including meningitis and septicemia. - The market outlook signals where vaccine demand, public health spending and immunization policy may move next. - Expanding vaccination coverage could affect disease prevention efforts across children, adolescents and other eligible groups.

What happened: - The Business Research Company published the Bexsero Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the global Bexsero market is expected to keep growing through 2035. - The report includes a free sample download: Download a free sample of the Bexsero market report. - The report also offers full access here: View the full Bexsero market report.

The details: - The report says historic growth was driven by meningococcal disease outbreaks, pediatric vaccination campaigns, regulatory approvals for group B vaccines, higher public health awareness and government procurement. - Future growth is expected to come from expanded adolescent vaccination, higher public health funding, better vaccine coverage, stronger outbreak preparedness and global immunization initiatives. - Forecast trends include broader meningococcal vaccination programs, a stronger focus on pediatric immunization, government-led health campaigns, rising awareness of invasive meningococcal disease and inclusion of Bexsero in national immunization schedules. - Bexsero is intended for active immunization in people 2 months and older. - The vaccine is designed to reduce the risk of severe disease caused by Neisseria meningitidis group B. - The report says rising meningitis cases are helping drive demand for preventive vaccines. - The UK Health Security Agency reported 378 cases of invasive meningococcal disease in 2024-25, up from 341 cases the prior year. - The report says ongoing research and development supports better vaccine formulation, safety, effectiveness and use in new populations. - Eurostat reported that government R&D funding in the European Union reached an estimated €127,916 million in 2024, up 3.4% from €123,675 million in 2023. - North America held the largest share of the Bexsero market in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future-trend analysis, plus updated graphics and tables.

Between the lines: - The report frames Bexsero as part of a broader shift toward routine meningococcal prevention rather than outbreak-only response. - Rising government funding and stronger national immunization planning appear to be key market catalysts, not just scientific advances. - Regional growth patterns suggest the market is still concentrated in mature vaccine systems, while faster expansion may come from newer or broader adoption markets.

What’s next: - The report expects more countries to add or expand Bexsero use in national schedules. - Adolescent vaccination programs and government-funded immunization campaigns could become stronger demand drivers. - Faster growth in Asia-Pacific may reshape the market mix over the forecast period.

The bottom line: - Bexsero’s market story is shifting from outbreak response to broader prevention, with policy, funding and schedule inclusion likely to determine how fast adoption grows.